Fasting plasma glucose is an independent predictor of survival in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
Milana BergaminoAntonio J RullanMaria SaigíInmaculada PeiróEduard MontanyaRamón PalmeroJosé Carlos RuffinelliArturo NavarroMaría Dolores ArnaizIsabel BraoSamantha AsoSusana PadronesFelipe CardenalErnest NadalPublished in: BMC cancer (2019)
Baseline FPG level is an independent predictor of survival in our cohort of patients with locally advanced NSCLC treated with concurrent chemoradiotherapy. Studies in larger cohorts of patients are warranted to confirm this relevant association.
Keyphrases
- locally advanced
- rectal cancer
- neoadjuvant chemotherapy
- squamous cell carcinoma
- phase ii study
- radiation therapy
- newly diagnosed
- end stage renal disease
- small cell lung cancer
- ejection fraction
- blood glucose
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- insulin resistance
- free survival
- type diabetes
- adipose tissue
- patient reported
- brain metastases